Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.006,36
0,19%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Monopar Therapeutics Inc (MNPR) Monopar Therapeutics Inc (MNPR) Notizie

Monopar Therapeutics Inc

MNPR
0,734
0,074 (11,21%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
18/4/202414:00GLOBEMonopar Announces Radiopharma Presentation Selected for..
16/4/202414:00GLOBEMonopar Announces Filing of Patent Protecting MNPR-101..
10/4/202414:00GLOBEMonopar Initiates Radiopharma Phase 1 Clinical Trial for..
28/3/202412:00GLOBEMonopar Reports Fourth Quarter and Full-Year 2023 Financial..
07/3/202414:30EDGAR2Form 8-K - Current report
05/3/202413:00EDGAR2Form 8-K - Current report
05/3/202413:00GLOBEMonopar Announces Positive Preclinical Therapeutic Isotope..
28/2/202419:45EDGAR2Form 8-K - Current report
27/2/202413:00GLOBEMonopar Provides Update on MNPR-101-Zr Radiopharma Clinical..
27/2/202412:59EDGAR2Form 8-K - Current report
22/2/202413:00EDGAR2Form 8-K - Current report
22/2/202413:00GLOBEMonopar Announces Promising Preclinical Data for its..
20/2/202414:00EDGAR2Form 8-K - Current report
20/2/202414:00GLOBEMonopar Receives Clearance to Proceed with First-in-Human..
04/1/202401:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202401:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202313:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202313:00EDGAR2Form 8-K - Current report
09/11/202313:00GLOBEMonopar Therapeutics Reports Third Quarter 2023 Financial..
01/11/202312:00EDGAR2Form 8-K - Current report
01/11/202312:00GLOBEMonopar Presents Data Showing Tumor Reduction Benefit of..
10/10/202313:00GLOBEMonopar to Participate in the Roth MKM 2023 Healthcare..
04/10/202301:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202301:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202313:00GLOBEMonopar to Participate in the H.C. Wainwright 25th Annual..
30/8/202323:16EDGAR2Form 8-K - Current report
10/8/202313:00EDGAR2Form 8-K - Current report
10/8/202313:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202313:00GLOBEMonopar Therapeutics Reports Second Quarter 2023 Financial..
08/8/202313:00EDGAR2Form 8-K - Current report
08/8/202313:00GLOBEMonopar Provides Encouraging Camsirubicin Clinical Data..
11/7/202313:00EDGAR2Form 8-K - Current report
11/7/202313:00GLOBEMonopar Announces MNPR-101 Radiopharma Collaboration..
04/7/202300:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/7/202300:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/6/202322:13EDGAR2Form 8-K - Current report
21/6/202313:00GLOBEMonopar to Participate in the Radiopharma Forum by the Lake..
14/6/202313:00GLOBEMonopar to Participate in the Maxim Group’s Healthcare..
01/6/202313:00GLOBEMonopar Announces Encouraging Camsirubicin Phase 1b Trial..
11/5/202313:00GLOBEMonopar Therapeutics Reports First Quarter 2023 Financial..
Apertura: 0,67 Min: 0,6433 Max: 0,7624
Chiusura: 0,66

La tua Cronologia

NASDAQ
MNPR
Monopar Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network